[ad_1]
- This partnership agreement marks the first joint marketing and sales collaboration for the ALZET osmotic pump portfolio and related product lines in the United States. Canada
- The companies plan to jointly market and commercialize the ALZET product line to customers over a multi-year period.
Cupertino, California , March 4, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories for the ALZET® osmotic pump portfolio and related product lines in the United States and United States. Canada. charles river is a globally recognized provider of drug discovery and non-clinical development solutions.
The Charles River Research Models & Services (RMS) sales and marketing team will work with DURECT to jointly market and commercialize the ALZET product line over a multi-year period to existing and new customers in the pharmaceutical industry and academic research institutions. will become. Charles River RMS will provide dedicated marketing resources and work with DURECT to develop and deploy a wide range of sales and marketing initiatives for ALZET. DURECT will continue to be responsible for manufacturing, marketing support, order fulfillment, and customer billing.
“DURECT and the Charles River RMS team are excited about this synergistic commercial partnership,” said James E. Brown, DVM, president and CEO of DURECT. “Both teams look forward to working together to raise awareness of ALZET and promote and expand ALZET sales throughout the United States.” Canada. ”
About ALZET Osmotic Pump
The ALZET product line consists of small implantable pumps and various accessories for experimental research in mice, rats, and other laboratory animals. ALZET pumps continuously deliver drugs, hormones, and other test agents at a controlled rate for periods ranging from one day to six weeks. Eliminates the need for external connections, frequent handling, or repeated dosing. The extensive use and application of the ALZET product line is evidenced by his over 22,000 references in the scientific literature. ALZET pumps are not approved and not intended for human use. For more information about the ALZET product line, please visit https://www.alzet.com/.
About Durect Co., Ltd.
DURECT is a late-stage company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer. is a biopharmaceutical company. DURECT’s lead drug candidate, larcosterol, is elevated in patients with alcohol-related hepatitis (AH) and binds to and inhibits the activity of DNA methyltransferase (DNMT), an epigenetic enzyme associated with hypermethylation. . Lalcosterol is in clinical development as a potential treatment for AH, and the FDA has granted Fast Track designation. In addition, his POSIMIR® (bupivacaine solution) for infiltration, a non-opioid analgesic that utilizes the innovative SABER® platform technology, has received FDA approval and is sold and distributed in the United States by his Innocoll Pharmaceuticals. Exclusively licensed. America. For more information about DURECT, visit www.durect.com and follow X (formerly Twitter) https://x.com/DURECTCorp.
DURECT’s forward-looking statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 relating to: Saving Lives, Plans to Meet with FDA to Review AHFIRM Study Results and Phase 3 Registration Study Design in Q1 2024, Possible FDA or Other Regulatory Authority Approval of Lalcostosterol for the Treatment of AH commercialization of POSIMIR, Innocoll’s potential development of larcostosterol for AH, NASH or other indications, and the potential benefits, if any, of our product candidates; Actual results may differ materially from those contained in the forward-looking statements contained in this press release, and the reported results should not be considered as an indication of future performance. Potential risks and uncertainties that could cause actual results to differ from those predicted include, among other things, future larcosterol clinical trials, subset analyzes of the AHFIRM trial, including geographic or other segmentation; involves the risk that the results will not be confirmed. The safety or efficacy of ralcosterol has not been demonstrated in early clinical or preclinical studies or in a statistically significant manner, and the FDA or other government agency approves ralcosterol as a treatment for AH. risks that Innocoll may not be able to successfully commercialize POSIMIR, and the sufficiency of our cash resources, anticipated capital requirements and need or desire for additional financing; , our ability to meet the minimum bid for continued listing on Nasdaq, risks related to our ability to raise capital to fund our operations and expenses, and our ability to continue to operate as a going concern; . Further information regarding these and other risks is contained in DURECT’s most recent Securities and Exchange Commission (SEC) filings, including its Annual Report on Form 10-K for the year ended. December 31, 2022 Quarterly Report on Form 10-Q for the Ended Quarter September 30, 2023, which will be listed under the heading “Risk Factors” when submitted. These reports are available on the “Investors” tab on our website at www.durect.com and on the SEC’s website at www.sec.gov. All information provided in this press release and the attachments is based on information available to DURECT as of the date of this press release and, except as required by law, does not reflect future events or We undertake no obligation to update this information as a result of developments.
Note: Posimir® SABER is a trademark of Innocoll Pharmaceuticals, Ltd. in the United States and DURECT Corporation outside the United States.® is a trademark of Durect Co., Ltd. Other referenced trademarks are the property of their respective owners. Lalcosterol is an investigational drug candidate under development and has not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.
Source Direct Co., Ltd.
[ad_2]
Source link
